Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC
Patients Characteristics, Treatment Utilization, Costs and Outcomes in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) Who Received at Least One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy in Taiwan
Sponsor: Ipsen
This observational or N/A phase trial investigates Renal Cell Carcinoma and Renal Cell Carcinoma Metastatic and is currently completed. Ipsen leads this study, which shows 11 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Sep 2019 — Jan 2021 [monthly]
Completed
Status: Recruiting → Completed
-
Aug 2019 — Sep 2019 [monthly]
Recruiting
▶ Show 6 earlier versions
-
Jun 2019 — Aug 2019 [monthly]
Recruiting
-
May 2019 — Jun 2019 [monthly]
Recruiting
-
Apr 2019 — May 2019 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jan 2019 — Apr 2019 [monthly]
Not Yet Recruiting
-
Dec 2018 — Jan 2019 [monthly]
Not Yet Recruiting
-
Nov 2018 — Dec 2018 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ipsen
For direct contact, visit the study record on ClinicalTrials.gov .